EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Patient Journey, Disease Burden, Treatment Patterns, and the Impact of Delayed Diagnosis Among Patients With Sjögren's Disease: A Real‐World US Survey

Anjana Lalla, Antton Egana, Jack Milligan, Nicola Massey, James Haughton

ACR Open Rheumatology · 2026-10 · 8 (10)

DOI: 10.1002/acr2.90143 ↗
AbstractBibliografische Angaben

Abstract

Objective The aim of this study was to investigate disease burden, treatment patterns, and impact of delayed diagnosis on patient outcomes in Sjögren's disease (SjD) in a real‐world setting in the United States. Methods Data were drawn from the Adelphi Primary Sjögren's Syndrome Disease Specific Programme, a US‐based cross‐sectional collaborative survey between rheumatologists and their next six consecutive consulting patients with SjD. Rheumatologists provided patients’ demographic and clinical information using medical records and a patient‐completed questionnaire. Results Rheumatologists (N = 84) provided data on 511 patients with SjD. Calculated Clinical EULAR Sjögren's Syndrome Disease Activity Index (ClinESSDAI)–proxy scores (ps) indicated that patients had mild (44.2%), moderate (30.9%), or severe (24.9%) disease. Among 297 patients, 33.7% had a EULAR Sjögren's Syndrome Patient‐Reported Index (ESSPRI)‐ps of ≥5. Descriptive trends in patient‐reported EuroQoL 5‐Dimension 3‐Level (EQ‐5D‐3L) utility, EuroQoL Visual Analog Scale (EQ‐VAS), Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT‐F), and Work Productivity and Activity Impairment questionnaire scores suggested worsening impairment with increasing SjD severity. Mean (±SD) time to diagnosis was 2.3 (±5.6) years. EQ‐5D‐3L utility ( P = 0.042), EQ‐VAS ( P = 0.026), FACIT‐F ( P = 0.007) scores, and ESSPRI‐ps ( P = 0.001) differed significantly by duration of diagnostic delay. The odds of ClinESSDAI‐ps and ESSPRI‐ps ≥5 at data collection were 2.3 and 2.1 times greater, respectively, in patients diagnosed >12 versus

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →